NGM Biopharmaceuticals, Inc. (NGM): Price and Financial Metrics

NGM Biopharmaceuticals, Inc. (NGM): $13.78

0.39 (+2.91%)

POWR Rating

Component Grades













Add NGM to Watchlist
Sign Up

Industry: Biotech



in industry

NGM Stock Price Chart Interactive Chart >

Price chart for NGM

NGM Price/Volume Stats

Current price $13.78 52-week high $27.25
Prev. close $13.39 52-week low $10.49
Day low $13.33 Volume 188,600
Day high $13.85 Avg. volume 294,019
50-day MA $14.41 Dividend yield N/A
200-day MA $17.57 Market Cap 1.09B

NGM Biopharmaceuticals, Inc. (NGM) Company Bio

NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.

NGM Latest News Stream

Event/Time News Detail
Loading, please wait...

NGM Latest Social Stream

Loading social stream, please wait...

View Full NGM Social Stream

Latest NGM News From Around the Web

Below are the latest news stories about Ngm Biopharmaceuticals Inc that investors may wish to consider to help them evaluate NGM as an investment opportunity.

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | February 20, 2022

NGM Bio (NGM) Up on Fast Track Tag For Ophthalmology Drug

The FDA bestows a Fast Track designation to NGM Bio's (NGM) product candidate, NGM621, for treating patients with geographic atrophy secondary to age-related macular degeneration. Stock up.

Yahoo | February 8, 2022

NGM Bio Shares Rise After Vision Disorder Candidate Receives FDA Fast Track Tag

The FDA has granted Fast Track designation to NGM Biopharmaceuticals Inc's (NASDAQ: NGM) NGM621, a monoclonal antibody to inhibit complement C3, for geographic atrophy (GA) secondary to age-related macular degeneration. NGM Bio is currently evaluating NGM621 in its ongoing Phase 2 CATALINA study, and a topline data readout is expected in Q4 of 2022. GA is an advanced form of age-related macular degeneration characterized by progressive retinal cell loss resulting in irreversible vision loss. NGM

Yahoo | February 7, 2022

NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3, for the treatment of patients with geographic atrophy (GA) secondary to age-relate

Yahoo | February 7, 2022

10 Best Biotech and AI Stocks To Buy According To Quant Billionaire Jim Simons

Euclidean Capital is the family office of billionaire hedge fund manager James “Jim” Simons. The hedge fund manages the private fortunes of Jim Simons, the 28th richest person in the world with a personal net worth of $24.4 billion as of January 28. Jim Simons is said to have revolutionized investing when he left academics […]

Yahoo | January 28, 2022

Read More 'NGM' Stories Here

NGM Price Returns

1-mo 10.42%
3-mo -7.27%
6-mo -23.53%
1-year -8.50%
3-year -4.50%
5-year N/A
YTD -22.19%
2021 -41.54%
2020 63.85%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7057 seconds.